Table of Content




1. Introduction
1.1. Definition of Idiopathic Pulmonary Fibrosis
1.2. Scope of the Report
1.3. Research Methodology


2. Executive Summary
2.1. Key Findings
2.2. Market Snapshot
2.3. Key Trends


3. Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Idiopathic Pulmonary Fibrosis
3.1.2. Advancements in Drug Development
3.1.3. Increasing Awareness and Early Diagnosis
3.1.4. Other Market Drivers
3.2. Market Restraints
3.2.1. High Treatment Costs
3.2.2. Limited Treatment Options
3.2.3. Regulatory and Reimbursement Challenges
3.2.4. Other Market Restraints
3.3. Market Opportunities
3.3.1. Development of Novel Therapies
3.3.2. Expansion in Emerging Markets
3.3.3. Growing Investments in R&D
3.3.4. Other Market Opportunities


4. Europe Idiopathic Pulmonary Fibrosis Market Analysis
4.1. Market Size and Forecast (2024-2034)
4.2. Market Share Analysis by:
4.2.1. Drug Class
4.2.1.1. MAPK Inhibitors
4.2.1.2. Tyrosine Kinase Inhibitors
4.2.1.3. Autotaxin Inhibitors
4.2.2. Route of Administration
4.2.2.1. Oral
4.2.2.2. Parenteral
4.2.3. Distribution Channel
4.2.3.1. Hospital Pharmacies
4.2.3.2. Retail Pharmacies
4.2.3.3. Online Pharmacies
4.3. Value Chain Analysis
4.4. SWOT Analysis
4.5. Porter’s Five Forces Analysis


5. Regional Market Analysis
5.1. Germany
5.1.1. Market Overview
5.1.2. Market Size and Forecast
5.1.3. Key Trends
5.1.4. Competitive Landscape
5.2. United Kingdom
5.2.1. Market Overview
5.2.2. Market Size and Forecast
5.2.3. Key Trends
5.2.4. Competitive Landscape
5.3. France
5.3.1. Market Overview
5.3.2. Market Size and Forecast
5.3.3. Key Trends
5.3.4. Competitive Landscape
5.4. Italy
5.4.1. Market Overview
5.4.2. Market Size and Forecast
5.4.3. Key Trends
5.4.4. Competitive Landscape
5.5. Spain
5.5.1. Market Overview
5.5.2. Market Size and Forecast
5.5.3. Key Trends
5.5.4. Competitive Landscape
5.6. Rest of Europe
5.6.1. Market Overview
5.6.2. Market Size and Forecast
5.6.3. Key Trends
5.6.4. Competitive Landscape


6. Competitive Landscape
6.1. Market Share Analysis of Key Players
6.2. Company Profiles of Key Players
6.2.1. Roche Holding AG
6.2.2. Boehringer Ingelheim GmbH
6.2.3. FibroGen, Inc.
6.2.4. Galapagos NV
6.2.5. Bristol-Myers Squibb Company
6.2.6. GlaxoSmithKline plc
6.2.7. AstraZeneca plc
6.2.8. Sanofi
6.2.9. Merck & Co., Inc.
6.2.10. Novartis AG
6.3. Recent Developments and Innovations
6.4. Strategic Initiatives


7. Future Outlook and Market Forecast
7.1. Market Growth Prospects
7.2. Technological Trends and Innovations
7.3. Investment Opportunities
7.4. Strategic Recommendations


8. Key Insights and Reiteration of Main Findings

9. Future Prospects for the Europe Idiopathic Pulmonary Fibrosis Market



List of Figures

List of Figures:

Figure 1: Europe Idiopathic Pulmonary Fibrosis Market: Market Segmentation
Figure 2: Europe Idiopathic Pulmonary Fibrosis Market: Research Methodology
Figure 3: Top Down Approach
Figure 4: Bottom Up Approach
Figure 5: Data Triangulation and Validation
Figure 6: Europe Idiopathic Pulmonary Fibrosis Market: Drivers, Restraints, Opportunities, and Challenges
Figure 7: Europe Idiopathic Pulmonary Fibrosis Market: Porter’s Five Forces Model Analysis
Figure 8: Europe Idiopathic Pulmonary Fibrosis Market: Value Chain Analysis
Figure 9: Europe Idiopathic Pulmonary Fibrosis Market Share Analysis, By Drug Class, 2024-2034
Figure 10: Europe Idiopathic Pulmonary Fibrosis Market Share Analysis, By Route of Administration, 2024-2034
Figure 11: Europe Idiopathic Pulmonary Fibrosis Market Share Analysis, By Distribution Channel, 2024-2034
Figure 12: Germany Idiopathic Pulmonary Fibrosis Market Share Analysis, By Drug Class, 2024-2034
Figure 13: Germany Idiopathic Pulmonary Fibrosis Market Share Analysis, By Route of Administration, 2024-2034
Figure 14: Germany Idiopathic Pulmonary Fibrosis Market Share Analysis, By Distribution Channel, 2024-2034
Figure 15: U.K. Idiopathic Pulmonary Fibrosis Market Share Analysis, By Drug Class, 2024-2034
Figure 16: U.K. Idiopathic Pulmonary Fibrosis Market Share Analysis, By Route of Administration, 2024-2034
Figure 17: U.K. Idiopathic Pulmonary Fibrosis Market Share Analysis, By Distribution Channel, 2024-2034
Figure 18: France Idiopathic Pulmonary Fibrosis Market Share Analysis, By Drug Class, 2024-2034
Figure 19: France Idiopathic Pulmonary Fibrosis Market Share Analysis, By Route of Administration, 2024-2034
Figure 20: France Idiopathic Pulmonary Fibrosis Market Share Analysis, By Distribution Channel, 2024-2034
Figure 21: Italy Idiopathic Pulmonary Fibrosis Market Share Analysis, By Drug Class, 2024-2034
Figure 22: Italy Idiopathic Pulmonary Fibrosis Market Share Analysis, By Route of Administration, 2024-2034
Figure 23: Italy Idiopathic Pulmonary Fibrosis Market Share Analysis, By Distribution Channel, 2024-2034
Figure 24: Spain Idiopathic Pulmonary Fibrosis Market Share Analysis, By Drug Class, 2024-2034
Figure 25: Spain Idiopathic Pulmonary Fibrosis Market Share Analysis, By Route of Administration, 2024-2034
Figure 26: Spain Idiopathic Pulmonary Fibrosis Market Share Analysis, By Distribution Channel, 2024-2034
Figure 27: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share Analysis, By Drug Class, 2024-2034
Figure 28: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share Analysis, By Route of Administration, 2024-2034
Figure 29: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share Analysis, By Distribution Channel, 2024-2034
Figure 30: Europe Idiopathic Pulmonary Fibrosis Market: Competitive Benchmarking
Figure 31: Europe Idiopathic Pulmonary Fibrosis Market: Vendor Share Analysis, 2024
Figure 32: Europe Idiopathic Pulmonary Fibrosis Market: Regulatory Landscape
Figure 33: Europe Idiopathic Pulmonary Fibrosis Market: Technological Innovations
Figure 34: Europe Idiopathic Pulmonary Fibrosis Market: Future Outlook
Figure 35: Europe Idiopathic Pulmonary Fibrosis Market: Forecast Methodology
Figure 36: Europe Idiopathic Pulmonary Fibrosis Market: Regional Demand Distribution
Figure 37: Europe Idiopathic Pulmonary Fibrosis Market: Price Trends and Forecast
Figure 38: Europe Idiopathic Pulmonary Fibrosis Market: Supply Chain Analysis
Figure 39: Europe Idiopathic Pulmonary Fibrosis Market: Consumer Preferences and Trends
Figure 40: Europe Idiopathic Pulmonary Fibrosis Market: Market Entry Strategies

List of Tables

List of Tables:

Table 1: Europe Idiopathic Pulmonary Fibrosis Market, By Drug Class, 2024-2034 (USD Million)
Table 2: Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2024-2034 (USD Million)
Table 3: Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2024-2034 (USD Million)
Table 4: Europe Idiopathic Pulmonary Fibrosis Market, By Country, 2024-2034 (USD Million)
Table 5: Germany Idiopathic Pulmonary Fibrosis Market, By Drug Class, 2024-2034 (USD Million)
Table 6: Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2024-2034 (USD Million)
Table 7: Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2024-2034 (USD Million)
Table 8: U.K. Idiopathic Pulmonary Fibrosis Market, By Drug Class, 2024-2034 (USD Million)
Table 9: U.K. Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2024-2034 (USD Million)
Table 10: U.K. Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2024-2034 (USD Million)
Table 11: France Idiopathic Pulmonary Fibrosis Market, By Drug Class, 2024-2034 (USD Million)
Table 12: France Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2024-2034 (USD Million)
Table 13: France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2024-2034 (USD Million)
Table 14: Italy Idiopathic Pulmonary Fibrosis Market, By Drug Class, 2024-2034 (USD Million)
Table 15: Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2024-2034 (USD Million)
Table 16: Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2024-2034 (USD Million)
Table 17: Spain Idiopathic Pulmonary Fibrosis Market, By Drug Class, 2024-2034 (USD Million)
Table 18: Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2024-2034 (USD Million)
Table 19: Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2024-2034 (USD Million)
Table 20: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Class, 2024-2034 (USD Million)
Table 21: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2024-2034 (USD Million)
Table 22: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2024-2034 (USD Million)
Table 23: Europe Idiopathic Pulmonary Fibrosis Market Revenue by Drug Class, 2024-2034 (USD Million)
Table 24: Europe Idiopathic Pulmonary Fibrosis Market Volume by Drug Class, 2024-2034 (Units)
Table 25: Europe Idiopathic Pulmonary Fibrosis Market Revenue by Route of Administration, 2024-2034 (USD Million)
Table 26: Europe Idiopathic Pulmonary Fibrosis Market Volume by Route of Administration, 2024-2034 (Units)
Table 27: Europe Idiopathic Pulmonary Fibrosis Market Revenue by Distribution Channel, 2024-2034 (USD Million)
Table 28: Europe Idiopathic Pulmonary Fibrosis Market Volume by Distribution Channel, 2024-2034 (Units)
Table 29: Europe Idiopathic Pulmonary Fibrosis Market Revenue by Country, 2024-2034 (USD Million)
Table 30: Europe Idiopathic Pulmonary Fibrosis Market Volume by Country, 2024-2034 (Units)
Table 31: Roche Holding AG: Company Snapshot
Table 32: Roche Holding AG: Operating Segments
Table 33: Roche Holding AG: Product Portfolio
Table 34: Boehringer Ingelheim International GmbH: Company Snapshot
Table 35: Boehringer Ingelheim International GmbH: Operating Segments
Table 36: Boehringer Ingelheim International GmbH: Product Portfolio
Table 37: FibroGen, Inc.: Company Snapshot
Table 38: FibroGen, Inc.: Operating Segments
Table 39: FibroGen, Inc.: Product Portfolio